RECRUITING

Developing Hyperpolarized Gas MRI Signatures to Detect and Manage Acute Cellular Rejection

Conditions

Lung Transplant Rejection lung transplant hyperpolarized xenon-129 MRI bronchoscopy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Lung transplantation (LT) is the only definitive therapy for many patients with end-stage lung diseases. The supply of donors' lungs is the biggest bottleneck to performing a lung transplant, and many patients die while waiting. Acute Cellular Rejection (ACR) is a significant risk factor for developing chronic allograft failure, a primary reason for death in this patient population. These observations highlight the importance of early diagnosis and management of ACR to prevent chronic graft failure. The preliminary results support the idea that Hyperpolarized Gas Magnetic Resonance Imaging has excellent potential to address this clinical gap. This study hypothesizes that optimized hyperpolarized gas magnetic resonance imaging (HGMRI) signatures can detect early pathophysiologic derangements in lung allografts consistent with ACR. This study also hypothesizes that the optimized HGMRI signatures will correlate with single-cell transcriptomic signatures that reflect dysregulated immune responses associated with ACR.

Official Title

Advanced Immunoclinical Phenotyping of Rejection in Lung Transplant

Quick Facts

Study Start:2024-05-01

Study Completion:2030-07-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT07046910

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* All subjects must be willing to participate and undergo the procedure, and be managed as outpatients * HXe MRI-specific Inclusion * All patients who successfully underwent a lung transplant at the University of Virginia * Followed by the medical lung transplant team for the post-lung transplant rejection surveillance program at the University of Virginia * a clinical diagnosis of lung transplant within the past 12 months * absence of any significant allograft dysfunction/rejection at the time of the 12-month surveillance bronchoscopy * the ability to understand a written informed consent form and comply with the requirements of the study. * have an acceptable pre-bronchoscopy pulmonary function test: FEV1\>45% before use of any bronchodilator * Must have acceptable pre-procedural screening studies. * Complete Blood Count: normal WBC, Hgb, and PLT * PT: Normal \< 1.2 * Basic Metabolic Panel: Normal 1. Scenario 1 (two visits): Standard bronchoscopy with Normal MRI results and without a diagnosis of acute rejection after bronchoscopy. 2. Scenario 2 (two visits): Navigational bronchoscopy with abnormal MRI result but without a diagnosis of acute rejection after bronchoscopy by clinical pathology. 3. Scenario 3 (three or four visits): Navigational bronchoscopy with abnormal MRI result and a diagnosis of acute rejection after bronchoscopy by clinical pathology at the first visit, the second visit, or both visits. 4. Scenario 4 (one visit): Subjects who previously signed Part 2 Substudy corresponding to the First HXe MRI visit of the Part 3 Substudy (6 or 12 month evaluation). They will be asked to join the Part 3 Substudy to undergo a 24-month follow-up evaluation, including MRI and bronchoscopy, as described for Scenarios 1, 2, or 3.	1. Unable to Consent 2. Continuous oxygen use at home. 3. Blood oxygen saturation of less than 92% as measured by pulse oximetry on the day of imaging. 4. FEV1 percent predicted less than 25%. 5. Pregnancy or lactation. 6. Claustrophobia, inner ear implants, aneurysms or other surgical clips, metal foreign bodies in the eye, pacemakers, or other contraindications to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded. 7. Chest circumference greater than that of the xenon MR and/or helium coil. The circumference of the coil is approximately 42 inches. 8. History of congenital cardiac disease, chronic renal failure, or cirrhosis. 9. Inability to understand simple instructions or to hold still for approximately 10 seconds. 10. History of respiratory infection within 2 weeks prior to the MR scan 11. History of MI, stroke, and/or poorly controlled hypertension. 12. Failure to complete study-related procedures 13. Unavailability of a reliable communication network and contacts for follow-up with the second in-house backup contact 14. Patient actively smokes. 15. Before 48 hours, any event being considered to be too risky to preclude surveillance bronchoscopy: SaO2 \<90%, \>16 puffs/24 hours of short-acting β-agonist (SABA), worsening symptoms prompting the use of any inhalers, FEV1 \< 45% before using a bronchodilator. 16. acute or chronic renal failure 17. uncontrolled coronary artery disease or congestive heart failure; uncontrolled diabetes mellitus; uncontrolled hypertension, liver disease; history of neurologic diseases, including stroke, any disease concerning fibrotic processes. 18. Pregnant females will be excluded 19. Claustrophobic or too large to fit into the available MR chest RF coils.

Inclusion Criteria

Exclusion Criteria

* All subjects must be willing to participate and undergo the procedure, and be managed as outpatients
* HXe MRI-specific Inclusion
* All patients who successfully underwent a lung transplant at the University of Virginia
* Followed by the medical lung transplant team for the post-lung transplant rejection surveillance program at the University of Virginia
* a clinical diagnosis of lung transplant within the past 12 months
* absence of any significant allograft dysfunction/rejection at the time of the 12-month surveillance bronchoscopy
* the ability to understand a written informed consent form and comply with the requirements of the study.
* have an acceptable pre-bronchoscopy pulmonary function test: FEV1\>45% before use of any bronchodilator
* Must have acceptable pre-procedural screening studies.
* Complete Blood Count: normal WBC, Hgb, and PLT
* PT: Normal \< 1.2
* Basic Metabolic Panel: Normal
1. Scenario 1 (two visits): Standard bronchoscopy with Normal MRI results and without a diagnosis of acute rejection after bronchoscopy.
2. Scenario 2 (two visits): Navigational bronchoscopy with abnormal MRI result but without a diagnosis of acute rejection after bronchoscopy by clinical pathology.
3. Scenario 3 (three or four visits): Navigational bronchoscopy with abnormal MRI result and a diagnosis of acute rejection after bronchoscopy by clinical pathology at the first visit, the second visit, or both visits.
4. Scenario 4 (one visit): Subjects who previously signed Part 2 Substudy corresponding to the First HXe MRI visit of the Part 3 Substudy (6 or 12 month evaluation). They will be asked to join the Part 3 Substudy to undergo a 24-month follow-up evaluation, including MRI and bronchoscopy, as described for Scenarios 1, 2, or 3.

1. Unable to Consent
2. Continuous oxygen use at home.
3. Blood oxygen saturation of less than 92% as measured by pulse oximetry on the day of imaging.
4. FEV1 percent predicted less than 25%.
5. Pregnancy or lactation.
6. Claustrophobia, inner ear implants, aneurysms or other surgical clips, metal foreign bodies in the eye, pacemakers, or other contraindications to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded.
7. Chest circumference greater than that of the xenon MR and/or helium coil. The circumference of the coil is approximately 42 inches.
8. History of congenital cardiac disease, chronic renal failure, or cirrhosis.
9. Inability to understand simple instructions or to hold still for approximately 10 seconds.
10. History of respiratory infection within 2 weeks prior to the MR scan
11. History of MI, stroke, and/or poorly controlled hypertension.
12. Failure to complete study-related procedures
13. Unavailability of a reliable communication network and contacts for follow-up with the second in-house backup contact
14. Patient actively smokes.
15. Before 48 hours, any event being considered to be too risky to preclude surveillance bronchoscopy: SaO2 \<90%, \>16 puffs/24 hours of short-acting β-agonist (SABA), worsening symptoms prompting the use of any inhalers, FEV1 \< 45% before using a bronchodilator.
16. acute or chronic renal failure
17. uncontrolled coronary artery disease or congestive heart failure; uncontrolled diabetes mellitus; uncontrolled hypertension, liver disease; history of neurologic diseases, including stroke, any disease concerning fibrotic processes.
18. Pregnant females will be excluded
19. Claustrophobic or too large to fit into the available MR chest RF coils.

Contacts and Locations

Study Contact

Carol Bampoe, BS

CONTACT

434.243.9634

cb3ff@uvahealth.org

Roselove Asare, MA

CONTACT

434.243.6074

rnn3b@uvahealth.org

Principal Investigator

Yun M Shim, MD

PRINCIPAL_INVESTIGATOR

University of Virginia

Study Locations (Sites)

University of Virginia

Charlottesville, Virginia, 22908

United States

Collaborators and Investigators

Sponsor: University of Virginia

Yun M Shim, MD, PRINCIPAL_INVESTIGATOR, University of Virginia

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-01

Study Completion Date2030-07-31

Study Record Updates

Study Start Date2024-05-01

Study Completion Date2030-07-31

Terms related to this study

Keywords Provided by Researchers

lung transplant
hyperpolarized xenon-129 MRI
bronchoscopy

Additional Relevant MeSH Terms

Lung Transplant Rejection